Evaluation of the effect of royal jelly on the side effects of methylprednisolone treatment

Evaluation of the effect of Royal Jelly Capsule on reducing the side effects of methylprednisolone treatment in patients with COVID-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210616051596N1

Enrollment

Registered

2022-01-02

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. Coronavirus infection, unspecified

Interventions

Intervention 1: Control group: Receiving the standard diet They receive 50 mg of methylprednisolone ampoules daily + placebo (daily for 7 days). Intervention 2: Intervention group: Standard diet ampou

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with positive PCR test who are treated with methylprednisolone.

Exclusion criteria

Exclusion criteria: Patients with diabetes, immune deficiency acute bacterial infectious disease allergy to bee products

Design outcomes

Primary

Measure	Time frame
Liver function factors (AST, ALT, ALKP, BILD, BILT). Timepoint: Daily. Method of measurement: Blood tet.;Renal function factors (Na, K, Cr and BUN). Timepoint: Daily. Method of measurement: Blood test.;Hematological factors (WBC, Hb, PLT). Timepoint: Daily. Method of measurement: Blood test.;FBS. Timepoint: Daily. Method of measurement: Blood test.;Dose and frequency of need for regular insulin (IR). Timepoint: Daily. Method of measurement: cheklist.;Dosage and frequency of corticosteroids. Timepoint: daily. Method of measurement: cheklist.;Clinical symptoms (chills, sore throat, abdominal pain, diarrhea, dyspnea, cough, shortness of breath). Timepoint: 7 day intervals. Method of measurement: Examination and questions.;Inflammatory factors (ferritin and LDH). Timepoint: 7 day intervals. Method of measurement: Blood test.;Disease severity. Timepoint: daily. Method of measurement: Need medical care, supportive oxygen, need mechanical ventilation.;Spo2. Timepoint: Daily. Method of measurement: Oximetry.	—

Measure

Time frame

Liver function factors (AST, ALT, ALKP, BILD, BILT). Timepoint: Daily. Method of measurement: Blood tet.;Renal function factors (Na, K, Cr and BUN). Timepoint: Daily. Method of measurement: Blood test.;Hematological factors (WBC, Hb, PLT). Timepoint: Daily. Method of measurement: Blood test.;FBS. Timepoint: Daily. Method of measurement: Blood test.;Dose and frequency of need for regular insulin (IR). Timepoint: Daily. Method of measurement: cheklist.;Dosage and frequency of corticosteroids. Timepoint: daily. Method of measurement: cheklist.;Clinical symptoms (chills, sore throat, abdominal pain, diarrhea, dyspnea, cough, shortness of breath). Timepoint: 7 day intervals. Method of measurement: Examination and questions.;Inflammatory factors (ferritin and LDH). Timepoint: 7 day intervals. Method of measurement: Blood test.;Disease severity. Timepoint: daily. Method of measurement: Need medical care, supportive oxygen, need mechanical ventilation.;Spo2. Timepoint: Daily. Method of measurement: Oximetry.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: Duration of hospitalization due to Covid-19. Method of measurement: File review.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Pourfard

Shahre-kord University of Medical Sciences

hamidhrpus@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026